LYMPHOMA, FOLLICULAR
Clinical trials for LYMPHOMA, FOLLICULAR explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, FOLLICULAR trials appear
Sign up with your email to follow new studies for LYMPHOMA, FOLLICULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Drug maintenance shows promise for lymphoma patients
Disease control OngoingThis study is for people with a type of blood cancer called follicular lymphoma that has returned after treatment. It compares two maintenance therapies after initial chemo: one uses a single drug (rituximab), the other uses a combination of two drugs (rituximab and lenalidomide,…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 17, 2026 11:34 UTC
-
New drug duo shows promise against lymphoma
Disease control OngoingThis study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma, a type of blood cancer. The drugs work together to help the immune system find and kill cancer cells. The main goal is to see how many patients have t…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for lymphoma patients: drug combo shows promise in early trial
Disease control OngoingThis study tests a new drug, golcadomide, combined with rituximab in 90 people with newly diagnosed advanced follicular lymphoma. The goal is to see if the combination can make the cancer disappear completely on scans. Participants must not have had prior treatment for this lymph…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug safety check for Hard-to-Treat lymphoma patients
Disease control OngoingThis study looks at the safety of the drug tazemetostat in people with a type of lymphoma (follicular lymphoma) that has come back or not responded to treatment and has a specific gene change (EZH2 mutation). About 145 participants in Japan will be observed during routine care to…
Matched conditions: LYMPHOMA, FOLLICULAR
Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
CAR t cell therapy: 15-Year safety check begins for lymphoma patients
Knowledge-focused OngoingThis study follows about 50 people who have already received an experimental CAR T cell therapy for certain types of lymphoma. The goal is to track any long-term side effects and survival for up to 15 years after treatment. No new study drug is given, but participants may receive…
Matched conditions: LYMPHOMA, FOLLICULAR
Sponsor: Adicet Therapeutics • Aim: Knowledge-focused
Last updated May 15, 2026 12:07 UTC